Compare ARK Genomic Revolution ETF (ARKG) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs NetEase Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while NetEase Inc trades at $131.66 (market cap $84.43B). The key difference: NetEase Inc pays a 2.36% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, NetEase Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NTES | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $43.57 | $159.34 |
52-Week Low | $23.09 | $109.26 |
Market Cap | — | $84.43B |
Enterprise Value | — | $60.90B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
NetEase (NTES) trades at $128.03, down 4.39% today, with strong fundamentals including 29.84% net income margin and $33.76B net income for 2025. The stock shows bullish technical signals with moving averages supporting upside, while RSI indicates potential overbought conditions. Recent Q1 2026 earnings beat expectations with $2.53 EPS versus $2.19 expected, demonstrating continued operational strength.
Wall Street maintains strong bullish sentiment with 82% buy ratings and 34.7% upside potential to analyst targets. Key risks include China market exposure and competitive gaming industry dynamics, but the company's $137.58B cash position and expanding international revenue provide solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
